Myovant Sciences Ltd and Pfizer Inc Collaboration To Develop and Commercialize Relugolix in Oncology and Women's Health Call Transcript
Ladies and gentlemen, thank you for standing by. And welcome to the Myovant Sciences conference call. Today's call is being recorded.
I would now like introduce your host for today's conference call, Mr. Ryan Crowe, Investor Relations at Myovant. You may begin.
Thank you, Kevin. Good morning, and welcome to Myovant Sciences conference call to discuss the relugolix collaboration in oncology and women's health between Myovant and Pfizer. Our press release for today's announcement as well as the slides we will present are available on our Investor Relations website, investors.myovant.com.
Joining me for today's call are Dr. Lynn Seely, Myovant's Chief Executive Officer; Frank Karbe, President and Chief Financial Officer; and Adele Gulfo, Interim Chief Commercial Officer; and Dr. Juan Camilo Arjona, Chief Medical Officer.
During this conference call, we'll be making forward-looking statements. These include plans and expectations with respect to our collaboration agreement, product, product
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |